Six-Month Intragastric Balloon Treatment for Obesity Improves Lung Function, Body Composition, and Metabolic Syndrome

Mafort, Thiago Thomáz; Madeira, Eduardo; Madeira, Miguel; Guedes, Erika Paniago; Moreira, Rodrigo O.; Mendonça, Laura Maria Carvalho de; Farias, Maria Lúcia Fleiuss; Lopes, Agnaldo José

doi:10.1007/s11695-013-1061-5

Cited by 24 publications

(12 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, decreased LV hypertrophy and improved LV function may occur following significant weight reduction [ 6 ]. The decrease in weight of the intragastric balloon therapy confirmed that of previous studies [ 11 ].…”

Section: Discussionsupporting

confidence: 89%

Effect of Weight Loss Induced by Intragastric Balloon Therapy on Cardiac Function in Morbidly Obese Individuals: A Pilot Study

Koç

Kayaoğlu²,

Çelik³

et al. 2015

Med Princ Pract

View full text Add to dashboard Cite

Objective: The aim of the study was to investigate the effect of intragastric balloon therapy on left ventricular function and left ventricular mass in a cohort of morbidly obese patients. Subjects and Methods: A prospective trial was performed in a cohort of 17 class II and class III morbidly obese individuals. The intragastric balloon was retained in the stomach for an average of 6 months. Conventional and tissue Doppler echocardiography were performed in all patients before and after the procedure. Results: The mean age of the study participants was 36 ± 10 years (range: 18-55). The mean body mass index was significantly decreased following the intragastric balloon insertion procedure (44 ± 8 vs. 38 ± 5, p < 0.001). The left ventricular mass index and left atrial volume index were significantly decreased following the procedure (112 ± 21 vs. 93 ± 17, p = 0.001 and 20 ± 6 vs. 14 ± 5, p = 0.02, respectfully). In addition, the ratio of mitral peak early diastolic velocity to tissue Doppler-derived peak diastolic velocity and tissue Doppler echocardiography-derived left ventricular myocardial performance index were decreased significantly following the procedure (9.5 ± 1.9 vs. 7.7 ± 1.5, p = 0.002 and 0.57 ± 0.11 vs. 0.46 ± 0.06, p = 0.001, respectively). Conclusions: Intragastric balloon therapy resulted in significant weight reduction in morbidly obese patients. This weight reduction was associated with improved left ventricular function.

show abstract

Section: Discussionsupporting

confidence: 89%

Effect of Weight Loss Induced by Intragastric Balloon Therapy on Cardiac Function in Morbidly Obese Individuals: A Pilot Study

Koç

Kayaoğlu²,

Çelik³

et al. 2015

Med Princ Pract

View full text Add to dashboard Cite

show abstract

“…Variations in body composition demonstrated by DXA included a total body fat decrease of 7.53 ± 7.62 kg (p < 0.0001), corresponding to 3.0 ± 3.4% (p < 0.001), and a total lean mass decrease of 3.70 ± 4.89 kg (p < 0.001). The complete anthropometric and DXA data results have been previously published [30]. …”

Section: Resultsmentioning

confidence: 99%

Impact of a 6-month treatment with intragastric balloon on body composition and psychopathological profile in obese individuals with metabolic syndrome

Guedes

Madeira

Mafort

et al. 2016

Diabetol Metab Syndr

Self Cite

View full text Add to dashboard Cite

BackgroundThe aim of this study was to investigate the effects of a 6-month treatment with intragastric balloon (IGB) on body composition and depressive/anxiety symptoms in obese individuals with metabolic syndrome (MS).MethodsFifty patients (aged 18–50 years) with obesity and MS were selected for treatment with IGB for 6 months. Body composition was verified with dual-energy X-ray absorptiometry (DXA) at baseline and right after IGB removal. Anxiety/depressive symptoms were assessed with the Beck Depression Inventory (BDI) and the hospital anxiety and depression scale (HADS) at baseline and after 6 months of treatment.ResultsIn total, 39 patients completed the study. After 6 months, there were significant decreases in weight (11.7 ± 9.6 kg, p < 0.0001) and waist circumference (9.3 ± 8.2 cm, p < 0.0001). Weight loss was also demonstrated by DXA and corresponded to decreases of 3.0 ± 3.4% in body fat percentage, 7.53 ± 7.62 kg in total body fat, and 3.70 ± 4.89 kg in lean body mass (p < 0.001 for all comparisons). Depressive symptoms scores decreased by a mean of 4.57 ± 10.6 points when assessed with the BDI (p = 0.002) and 1.82 ± 5.16 points when assessed with the HADS-Depression (p = 0.0345). Anxiety symptoms scores decreased by a mean of 1.84 ± 4.04 points when determined with the HADS-anxiety (p = 0.0066). The decrease in body fat percentage was the parameter that best correlated with improvements in depressive (p = 0.008) and anxiety symptoms (p = 0.014).ConclusionsIn obese individuals with MS, fat mass reduction was associated with short-term improvements in depressive and anxiety symptoms. Trial Registration Registered at ClinicalTrials.gov, NCT01598233

show abstract

“…After six months of intragastric balloon placement, 77.5% of subjects no longer met the diagnostic criteria for the metabolic syndrome in a sample of 40 previously overweight or obese patients with the metabolic syndrome. This procedure further reduced the percentage of truncal, android, gynoid and total fat (P=0.0001), and improved lung function parameters (68). In a small sample of obese patients treated with the BioEnterics intragastric balloon, the amount of weight loss experienced during the first month may be an important predictor of weight loss up to one year after balloon removal (18 months since baseline) (69).…”

Section: Use Of Intragastric Balloon and Changes In Adipokine Levelsmentioning

confidence: 88%

Nonmedicinal Interventions in Nonalcoholic Fatty Liver Disease

Neuman

Nanau

Cohen

2015

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Unhealthy diet and lack of physical exercise are responsible for fat accumulation in the liver, which may lead to liver disease. Histologically, the severity of the disease has two stages: nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). NAFLD is defined by the presence of steatosis with no evidence of cellular injury such as hepatocyte ballooning. NASH is a distinct entity from NAFLD, and is characterized by the presence of inflammation with hepatocytes damage, with or without fibrosis. While several therapeutic strategies have been proposed to improve this condition, the present review aims to discuss nonmedicinal interventions used to reduce liver involvement or to prevent the disease altogether. The authors investigated dietary patterns and vitamin deficiencies associated with NAFLD, and their role in enhancing disease severity. Additionally, they reviewed the role of exercise and the use of interventions, such as as intragastric balloon and bariatric surgery, for improving disease progression. The authors propose monitoring disease progression or repair by following changes in cytoadipokine levels.

show abstract

Six-Month Intragastric Balloon Treatment for Obesity Improves Lung Function, Body Composition, and Metabolic Syndrome

Abstract: IGB efficiently induced weight loss and promoted the improvement of lung function parameters, with a reduction of the restrictive ventilatory defect. It also promoted improvements of MS and the pattern of body fat distribution.

Cited by 24 publications

References 40 publications

Effect of Weight Loss Induced by Intragastric Balloon Therapy on Cardiac Function in Morbidly Obese Individuals: A Pilot Study

Effect of Weight Loss Induced by Intragastric Balloon Therapy on Cardiac Function in Morbidly Obese Individuals: A Pilot Study

Impact of a 6-month treatment with intragastric balloon on body composition and psychopathological profile in obese individuals with metabolic syndrome

Nonmedicinal Interventions in Nonalcoholic Fatty Liver Disease

Contact Info

Product

Resources

About